Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018).

González Del Alba A, De Velasco G, Lainez N, Maroto P, Morales-Barrera R, Muñoz-Langa J, Pérez-Valderrama B, Basterretxea L, Caballero C, Vazquez S.

Clin Transl Oncol. 2019 Jan;21(1):64-74. doi: 10.1007/s12094-018-02001-x. Epub 2018 Dec 18.

2.

Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.

Milowsky MI, Rumble RB, Booth CM, Gilligan T, Eapen LJ, Hauke RJ, Boumansour P, Lee CT.

J Clin Oncol. 2016 Jun 1;34(16):1945-52. doi: 10.1200/JCO.2015.65.9797. Epub 2016 Mar 21.

PMID:
27001593
3.

EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.

Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A; European Association of Urology.

Eur Urol. 2014 Apr;65(4):778-92. doi: 10.1016/j.eururo.2013.11.046. Epub 2013 Dec 12.

PMID:
24373477
4.

SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).

Lázaro M, Gallardo E, Doménech M, Pinto Á, González-del-Alba A, Del Alba AG, Puente J, Fernández O, Font A, Lainez N, Vázquez S.

Clin Transl Oncol. 2016 Dec;18(12):1197-1205. doi: 10.1007/s12094-016-1584-z. Epub 2016 Nov 29. Erratum in: Clin Transl Oncol. 2019 Jun;21(6):817. Del Alba AG [corrected to González-del-Alba A].

5.

Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.

Nadal R, Apolo AB.

Curr Treat Options Oncol. 2018 May 28;19(7):36. doi: 10.1007/s11864-018-0551-z. Review.

PMID:
29808294
6.

SEOM clinical guidelines for the treatment of invasive bladder cancer.

Morales R, Font A, Carles J, Isla D.

Clin Transl Oncol. 2011 Aug;13(8):552-9. doi: 10.1007/s12094-011-0696-8.

PMID:
21821489
7.

Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA; European Association of Urology (EAU).

Eur Urol. 2011 Jun;59(6):1009-18. doi: 10.1016/j.eururo.2011.03.023. Epub 2011 Mar 23. Review.

PMID:
21454009
8.

[Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines].

Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA; European Association of Urology.

Actas Urol Esp. 2012 Sep;36(8):449-60. Epub 2012 Mar 2. Spanish.

PMID:
22386114
9.

The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Murasawa H, Koie T, Ohyama C, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Iwabuchi I, Ogasawara M, Kawaguchi T.

Int J Clin Oncol. 2017 Feb;22(1):159-165. doi: 10.1007/s10147-016-1029-2. Epub 2016 Aug 17.

PMID:
27534866
10.

Immune checkpoint inhibitors for urothelial carcinoma.

Kim HS, Seo HK.

Investig Clin Urol. 2018 Sep;59(5):285-296. doi: 10.4111/icu.2018.59.5.285. Epub 2018 Aug 31. Review.

11.

Challenges in the treatment of bladder cancer.

Kaufman DS.

Ann Oncol. 2006 May;17 Suppl 5:v106-12. Review.

PMID:
16807436
12.

SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A.

World J Urol. 2019 Jan;37(1):61-83. doi: 10.1007/s00345-018-2606-y. Epub 2019 Jan 25. Review.

PMID:
30684034
13.
14.

Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions.

Aragon-Ching JB, Werntz RP, Zietman AL, Steinberg GD.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:307-318. doi: 10.1200/EDBK_201227. Review.

PMID:
30231340
15.

Neoadjuvant chemotherapy for bladder cancer.

Sonpavde G, Lerner SP.

Oncology (Williston Park). 2007 Dec;21(14):1673-81; discussion 1686-8, 1691, 1694. Review.

16.

Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.

Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL.

Lancet Oncol. 2013 Aug;14(9):863-72. doi: 10.1016/S1470-2045(13)70255-9. Epub 2013 Jul 1.

17.

[ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].

Pignot G, Houédé N, Roumiguié M, Audenet F, Brunelle S, Colin P, Compérat E, Larré S, Masson-Lecomte A, Neuzillet Y, Xylinas E, Méjean A, Rouprêt M; les membres du CCAFU Vessie.

Prog Urol. 2018 Oct;28(12):567-574. doi: 10.1016/j.purol.2018.07.003. Epub 2018 Sep 8. Review. French.

PMID:
30205925
18.

[Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].

Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA; European Association of Urology.

Actas Urol Esp. 2010 Jan;34(1):51-62. Spanish.

PMID:
20223133
19.

Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.

Narayan V, Mamtani R, Keefe S, Guzzo T, Malkowicz SB, Vaughn DJ.

Cancer Res Treat. 2016 Jul;48(3):1084-91. doi: 10.4143/crt.2015.405. Epub 2015 Dec 2.

20.

Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.

Vashistha V, Quinn DI, Dorff TB, Daneshmand S.

BMC Cancer. 2014 Dec 16;14:966. doi: 10.1186/1471-2407-14-966. Review.

Supplemental Content

Support Center